amendment
-
Financial
Vexim: Amendment of the financial agenda for 2017
Toulouse (France), January 30th, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in…
Read More » -
Financial
Vexim: Amendment of the financial agenda for 2016
Toulouse, September 2, 2016 –VEXIM (FR0011072602 – ALVXM / PEA‐PME), a medical device company specializing in the minimally invasive treatment…
Read More » -
Hospitals
Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria
WALTHAM, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More »